y6 receptor (npy6r_human)
FAMILY
Class A (Rhodopsin) Peptide receptors Neuropeptide Y receptors y6 receptor
GENE
NPY6R (NPY1RL, Y2B)
ORGANISM
Human (Homo sapiens)
ALT. NAMES
Putative neuropeptide Y receptor type 6, NPY6-R, NPY Y1-like receptor, Putative pancreatic polypeptide receptor 2, PP2
SOURCE
SWISSPROT
SEQUENCE
N-term | |||||||||
M
|
E
|
V
|
S
|
L
|
N
|
H
|
P
|
A
|
S
|
10 |
N
|
T
|
T
|
S
|
T
|
K
|
N
|
N
|
N
|
S
|
20 |
A
|
F
|
F
|
Y
|
F
|
E
|
S
|
C
|
Q
|
P
|
30 |
TM1 | |||||||||
P
|
S
|
P
|
A
|
L
|
L
|
L
|
L
|
C
|
I
|
40 |
A
|
Y
|
T
|
V
|
V
|
L
|
I
|
V
|
G
|
L
|
50 |
F
|
G
|
N
|
L
|
S
|
L
|
I
|
I
|
I
|
I
|
60 |
ICL1 | |||||||||
F
|
K
|
K
|
Q
|
R
|
K
|
A
|
Q
|
N
|
F
|
70 |
TM2 | |||||||||
T
|
S
|
I
|
L
|
I
|
A
|
N
|
L
|
S
|
L
|
80 |
S
|
D
|
T
|
L
|
V
|
C
|
V
|
M
|
C
|
I
|
90 |
H
|
F
|
T
|
I
|
I
|
Y
|
T
|
L
|
M
|
D
|
100 |
ECL1 | TM3 | ||||||||
H
|
W
|
I
|
F
|
G
|
D
|
T
|
M
|
C
|
R
|
110 |
L
|
T
|
S
|
Y
|
V
|
Q
|
S
|
V
|
S
|
I
|
120 |
S
|
V
|
S
|
I
|
F
|
S
|
L
|
V
|
F
|
T
|
130 |
A
|
V
|
E
|
R
|
Y
|
Q
|
L
|
I
|
V
|
N
|
140 |
ICL2 | TM4 | ||||||||
P
|
R
|
G
|
W
|
K
|
P
|
S
|
V
|
T
|
H
|
150 |
A
|
Y
|
W
|
G
|
I
|
T
|
L
|
I
|
W
|
L
|
160 |
F
|
S
|
L
|
L
|
L
|
S
|
I
|
P
|
F
|
F
|
170 |
ECL2 | |||||||||
L
|
S
|
Y
|
H
|
L
|
T
|
D
|
E
|
P
|
F
|
180 |
R
|
N
|
L
|
S
|
L
|
P
|
T
|
D
|
L
|
Y
|
190 |
T
|
H
|
Q
|
V
|
A
|
C
|
V
|
E
|
N
|
W
|
200 |
TM5 | |||||||||
P
|
S
|
K
|
K
|
D
|
R
|
L
|
L
|
F
|
T
|
210 |
T
|
S
|
L
|
F
|
L
|
L
|
Q
|
Y
|
F
|
V
|
220 |
P
|
L
|
G
|
F
|
I
|
L
|
I
|
C
|
Y
|
L
|
230 |
K
|
I
|
V
|
I
|
C
|
L
|
R
|
R
|
R
|
N
|
240 |
ICL3 | TM6 | |||||||||
A
|
K
|
V
|
D
|
K
|
K
|
K
|
E
|
N
|
E
|
|
250 |
G
|
R
|
L
|
N
|
E
|
N
|
K
|
R
|
I
|
N
|
260 |
T
|
M
|
L
|
I
|
S
|
I
|
V
|
V
|
T
|
F
|
270 |
G
|
A
|
C
|
W
|
L
|
P
|
R
|
I
|
S
|
S
|
280 |
M
|
S
|
S
|
L
|
T
|
G
|
I
|
M
|
R
|
C
|
290 |
LINKS
DIAGRAMS
Pick color:
Invitro Mutant Data: Increased binding/potency: >5-fold, >10-fold; Reduced binding/potency: >5-fold, >10-fold; No/low effect (<5-fold); and N/A
Pick color:
Invitro Mutant Data: Increased binding/potency: >5-fold, >10-fold; Reduced binding/potency: >5-fold, >10-fold; No/low effect (<5-fold); and N/A
MUTATIONS
PHYSIOLOGICAL LIGANDS
No physiological ligands available
STRUCTURE MODELS
STRUCTURES
No structures available